New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
10:27 EDTCANFCan-Fite CF102 approved for compassionate use in Israel
Can-Fite BioPharma announced that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. The program allows doctor-initiated single-patient access to investigational treatments for innovative or investigational products not yet registered in any country worldwide. Can-Fite has also previously received Orphan Drug Designation from the U.S. FDA for CF102 in the treatment of advanced hepatocellular carcinoma.
News For CANF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2015
10:13 EDTCANFCan-Fite BioPharma to present CF101 psoriasis data at EADV Congress
Can-Fite BioPharma announced that CEO Dr. Pnina Fishman will present data at the 24th European Academy of Dermatology and Venereology's Congress in Copenhagen, Denmark on Saturday, October 10. The presentation titled, "Treatment of Plaque-type Psoriasis with Oral CF101: Data from a Phase II/III Clinical Trial," will be part of the Late Breaking News session. Can-Fite previously reported positive data from further analysis of its completed Phase II/III study that suggests CF101 as a potential systemic therapy for patients with moderate-severe psoriasis, this despite the study not meeting its primary endpoint, as previously announced during the first quarter of 2015. Based on these findings, Can-Fite expects to complete the design of its Phase III study protocol by the end of 2015.
September 21, 2015
08:09 EDTCANFCan-Fite BioPharma announces $9M registered direct offering
Can-Fite BioPharma announced it will issue 2,068,966 registered American Depository Shares, or ADSs, of Can-Fite at a purchase price of $4.35 per ADS in a registered direct offering. Additionally, for each ADS purchased by investors, the investors will receive an unregistered warrant to purchase one-half of an ADS. The warrants have an exercise price of $5.25 per ADS, shall be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. H.C. Wainwright & Co. acted as the exclusive placement agent in connection with this offering.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use